Begin main content

RFA: Inlyta for Metastatic Renal Cell Carcinoma

Project Number pCODR RFA 0001
Brand Name Inlyta
Generic Name Axitinib
Tumour Type Genitourinary
Indication Metastatic Renal Cell Carcinoma
Funding Request RFA Question from the Provincial Advisory Group Is there evidence to fund axitinib as an alternative to everolimus for the second-line treatment of metastatic clear cell renal carcinoma?
Review Status Under Review
Pre Noc Submission
NOC Date
Manufacturer Pfizer Canada Inc.
Submitter pCODR Provincial Advisory Group
Submission Date April 18, 2017
Submission Type Request for Advice
Prioritization Requested
Stakeholder Input Deadline ‡ May 2, 2017
pERC Meeting June 16, 2017
Clarification Please note that the June pERC meeting was conducted over two days. The target for the posting of pERC Initial Recommendation remains as June 29, 2017.
Final Recommendation Issued (target date) June 29, 2017
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.